Clinical Characteristics and Outcome of Gleason Score 10 Prostate Cancer on Core Biopsy Treated by External Radiotherapy and Hormone Therapy

Mai Zhi-peng; Yan Wei-gang; Li Han-zhong; Ji Zhi-gang; Zhang Fu-quan; Hu Ke; Xiao Yu

Your Location：

Home >

Browse articles >

Clinical Characteristics and Outcome of Gleason Score 10 Prostate Cancer on Core Biopsy Treated by External Radiotherapy and Hormone Therapy

Chinese Medical Sciences Journal Vol. 30, Issue 2, Pages: 90-94(2015)

Original Articles | Updated：2024-04-10

- Clinical Characteristics and Outcome of Gleason Score 10 Prostate Cancer on Core Biopsy Treated by External Radiotherapy and Hormone Therapy
- Affiliations：
  
  1. 1Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China;
  2. 2Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China;
  3. 3Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China;
- Author bio：
  
  *Corresponding author Tel: 86-10-69152520, E-mail: yanwg111@126.com
- Funds：
- DOI：
  CLC：
- Received：03 January 2015，
  
  Published Online：20 April 2015，
  
  Published：2015-04
- Accepted：
Scan QR Code
Mai Zhi-peng, Yan Wei-gang, Li Han-zhong, et al. Clinical Characteristics and Outcome of Gleason Score 10 Prostate Cancer on Core Biopsy Treated by External Radiotherapy and Hormone Therapy[J]. Chinese medical sciences journal, 2015, 30(2): 90-94.
DOI：

Mai Zhi-peng, Yan Wei-gang, Li Han-zhong, et al. Clinical Characteristics and Outcome of Gleason Score 10 Prostate Cancer on Core Biopsy Treated by External Radiotherapy and Hormone Therapy[J]. Chinese medical sciences journal, 2015, 30(2): 90-94. DOI：

摘要

Abstract

Objective

To evaluate the clinical characteristics and outcomes of patients with Gleason score 10 prostate cancer treated by external radiotherapy and hormone therapy.

Methods

From January 2003 to March 2014

1832 patients with prostate cancer were treated

among which 9 patients (represented 0.49%) were identified as Gleason score 10 disease on prostate core biopsy without distant metastases when first diagnosed. All 9 patients were treated by whole pelvic external radiotherapy (The whole pelvic dose was 50.0 Gy and the boost dose ranged from 76.2 to 78.0 Gy) and long-term hormone therapy. We assessed the clinical characteristics

treatment outcomes and treatment toxicities. Survival curves were calculated using the Kaplan-Meier method.

Results

The median follow-up was 4.8 years. Six patients’ pre-treatment prostate-specific antigen (PSA) levels were lower than 20.0 μg/L and three patients’ pre-treatment PSA levels were higher than 70.0 μg/L. The median percentage of positive biopsy cores was 91%. Three

four and two cases were classified as T2c

T3a and T3b stage

respectively. Three cases were assessed as N1 stage. The 5-year biochemical failure-free survival

distant metastasis-free survival

cancer specific survival and overall survival rates were 28.6%

57.1%

66.7% and 57.1%

respectively. Five patients experienced grade 1-2 acute gastrointestinal toxicities and six patients complained of grade 1-2 acute genitourinary toxicities. No bone fracture or cardiovascular disease was detected.

Conclusions

Gleason score 10 prostate cancer on core biopsy is usually combined with other high risk factors. The pre-treatment PSA levels lie in two extremes. Timely and active treatments are urgent needed because unfavourable oncological outcomes are often presented.

关键词

Keywords

references

Nanda A , Chen M , Renshaw A , et al. Gleason pattern 5 prostate cancer: Further stratification of patients with high-risk disease and implications for future randomized trials. Int J Radiat Oncol Biol Phys 2009 ; 74 : 1419 - 23 .

McGuire BB , Helfand BT , Loeb S , et al . Outcomes in patients with Gleason score 8-10 prostate cancer: Relation to preoperative PSA level. BJU Int 2012 ; 109 : 1764 - 9 .

Krauss DJ , Hayek S , Amin M , et al. Prognostic significance of neuroendocrine differentiation in patients with Gleason score 8-10 prostate cancer treated with primary radiotherapy. Int J Radiat Oncol Biol Phys 2011 ; 81 : 119 - 25 .

Serni S , Masieri L , Minervini A , et al. Cancer progression after anterograde radical prostatectomy for pathologic Gleason score 8 to 10 and influence of concomitant variables. Urology 2006 ; 67 : 373 - 8 .

Stock R , Cesaretti J , Hall S , et al. Outcomes for patients with high-grade prostate cancer treated with a combination of brachytherapy, external beam radiotherapy and hormonal therapy. BJU Int 2009 ; 104 : 1631 - 6 .

Ellis CL , Partin AW , Han M , et al. Adenocarcinoma of the prostate with Gleason score 9-10 on core biopsy: Correlation with findings at radical prostatectomy and prognosis. J Urol 2013 ; 190 : 2068 - 73 .

Humphrey PA. Gleason pattern 5 adenocarcinoma in prostate needle biopsy. J Urol 2012 ; 188 : 1341 - 2 .

Consensus Consensus statement: Guidelines for PSA following radiation therapy . American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 1997 ; 37 : 1035 - 41 .

Sabolch A , Feng F , Daignault-Newton S , et al. Gleason pattern 5 is the greatest risk factor for clinical failure and death from prostate cancer after dose-escalated radiation therapy and hormonal ablation. Int J Radiat Oncol Biol Phys 2011 ; 81 : 351 - 60 .

D'Ambrosio DJ , Hanlon AL, Al-Saleem T , et al . The proportion of prostate biopsy tissue with Gleason pattern 4 or 5 predicts for biochemical and clinical outcome after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2007 ; 67 : 1082 - 7 .

Lughezzani G , Gallina A , Larcher A , et al. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer. BJU Int 2013 ; 111 : 723 - 30 .

Pahlajani N , Ruth KJ , Buyyounouski MK , et al. Radiotherapy doses of 80 Gy and higher are associated with lower mortality in men with Gleason score 8 to 10 prostate cancer. Int J Radiat Int J Radiat Oncol Biol Phys 2012 ; 82 : 1949 - 56 .

D'Amico AV , Chen MH, Renshaw AA , et al . Androgen suppression and radiation vs . radiation alone for prostate cancer: A randomized trial. JAMA 2008 ; 299 : 289 - 95 .

Pilepich MV , Winter K , Lawton CA , et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—long-term results of phase Ⅲ RTOG 85-31. Int J Radiat Oncol Biol Phys 2005 ; 61 : 1285 - 90 .

Zelefsky MJ , Pei X , Chou JF , et al. Dose escalation for prostate cancer radiotherapy: Predictors of long- term biochemical tumor control and distant metastases-free survival outcomes. Eur Urol 2011 ; 60 : 1133 - 9 .

Bolla M , de Reijke TM , Van Tienhoven G , et al . Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009 ; 11 : 2516 - 27 .

Weir EG , Partin AW , Epstein JI. Correlation of serum prostate specific antigen and quantitative immunohistochemistry. J Urol 2000 ; 163 : 1739 - 42 .

Inman BA , DiMarco DS, Slezak JM , et al . Outcomes of Gleason score 10 prostate carcinoma treated by radical prostatectomy. Urology 2006 ; 68 : 604 - 8 .

Views

1454

Downloads

CSCD

Alert me when the article has been cited

Submit

Publicity Resources

Outcomes of T3a Prostate Cancer with Unfavorable Prognostic Factors Treated with Brachytherapy Combined with External Radiotherapy and Hormone Therapy

Related Author

Yan* Wei-gang

Zhou Yi

Zhou Zhi-en

Related Institution

No data

⁰